Hama Satoshi, Akiyama Mitsuhiro, Higashida-Konishi Misako, Oshige Tatsuhiro, Takei Hiroshi, Izumi Keisuke, Oshima Hisaji, Okano Yutaka
Division of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Mod Rheumatol Case Rep. 2023 Jan 3;7(1):92-95. doi: 10.1093/mrcr/rxac049.
Anti-melanoma differentiation-associated gene 5 (MDA5) antibody is associated with clinically amyopathic dermatomyositis (CADM) with rapidly progressive interstitial lung disease (RP-ILD). Recently, several studies have reported that tofacitinib (TOF), a Janus kinase inhibitor, might be effective for cases of new or refractory RP-ILD in anti-MDA5 antibody-positive CADM; however, it is unknown whether TOF can also be effective for relapsed cases. We herein report a relapsed case of RP-ILD in anti-MDA5 antibody-positive CADM, which was successfully treated by combination therapy with TOF (5 mg twice daily). Our case suggests that TOF may also be a potential treatment option for relapsed cases of this disease.
抗黑色素瘤分化相关基因5（MDA5）抗体与伴有快速进展性间质性肺病（RP-ILD）的临床无肌病性皮肌炎（CADM）相关。最近，几项研究报告称，Janus激酶抑制剂托法替布（TOF）可能对抗MDA5抗体阳性CADM的新发或难治性RP-ILD病例有效；然而，TOF对复发病例是否也有效尚不清楚。我们在此报告1例抗MDA5抗体阳性CADM的RP-ILD复发病例，该病例通过TOF（每日2次，每次5 mg）联合治疗成功治愈。我们的病例表明，TOF可能也是该疾病复发病例的一种潜在治疗选择。
